(Q30224496)

10 June 2017

title

Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia (English)

1 reference

10 June 2017

0 references

0 references

0 references

pandemic preparedness

1 reference

Roland Ventura

1

1 reference

10 June 2017

Livia Brunner

2

1 reference

10 June 2017

Bambang Heriyanto

3

1 reference

10 June 2017

Otto de Boer

4

1 reference

10 June 2017

Michael O'Hara

5

1 reference

10 June 2017

Chuong Huynh

6

1 reference

10 June 2017

Mahendra Suhardono

7

1 reference

10 June 2017

Nicolas Collin

8

1 reference

10 June 2017

language of work or name

English

0 references

publication date

8 August 2012

1 reference

10 June 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

10 June 2017

volume

31

1 reference

10 June 2017

issue

12

1 reference

10 June 2017

page(s)

1641-1645

1 reference

The Vaccine Formulation Laboratory: a platform for access to adjuvants

10 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

Establishment of pandemic influenza vaccine production capacity at Bio Farma, Indonesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

Technology transfer hub for pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.074

10.1016/J.VACCINE.2012.07.074

7 January 2021

Identifiers

DOI

1 reference

10 June 2017

1 reference